Multinational pharmaceutical companies in Vietnam say they are pleased with new laws easing the right to import and distribute drugs, but hope for even more action by the government to bring regulations in line with international norms. Vietnam became a member of the World Trade Organization effective Jan. 11, but representatives of foreign drug makers quickly cited other moves the country needs to make before they can operate more efficiently. Representatives of GlaxoSmithKline, Zuellig Pharma Vietnam and Korea United Pharma discussed the improved conditions for pharmaceutical makers in Vietnam. (Click here for more)
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
Recent moves in the industry include changes at the top at Meitheal Pharmaceuticals, Ardelyx and AIRNA, plus five companies get new CMOs.
Ibrance is losing share to other drugs, but Zydus looks forward to a late 2027/early 2028 launch of its generic in the US where partner Synthon might have 180-day exclusivity. In India, as Lilly launches Mounjaro KwikPen, it hopes for a GLP-1 edge with a differentiated device and formulation.
Sarepta is in a cash crunch with sales of Elevidys slumping due to safety concerns and with financial commitments coming due, including debt repayments and milestone fees for its partner Arrowhead.
